AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma
{{output}}
Bispecific antibodies (bsAbs) are an emerging treatment modality particularly in hematologic malignancies such as the non-Hodgkin lymphomas follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Although bsAbs offer opportunities in the treatment ... ...
